Stock Research for INSY

INSY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

INSY Stock Chart & Research Data

The INSY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INSY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


INSY Due diligence Resources & Stock Charts

The INSY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View INSY Detailed Price Forecast - CNN Money CNN View INSY Detailed Summary - Google Finance
Yahoo View INSY Detailed Summary - Yahoo! Finance Zacks View INSY Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View INSY Trends & Analysis - Trade-Ideas Barrons View INSY Major Holders - Barrons
NASDAQ View INSY Call Transcripts - NASDAQ Seeking View INSY Breaking News & Analysis - Seeking Alpha
Spotlight View INSY Annual Report - CompanySpotlight.com OTC Report View INSY OTC Short Report - OTCShortReport.com
TradeKing View INSY Fundamentals - TradeKing Charts View INSY SEC Filings - Bar Chart
WSJ View Historical Prices for INSY - The WSJ Morningstar View Performance/Total Return for INSY - Morningstar
MarketWatch View the Analyst Estimates for INSY - MarketWatch CNBC View the Earnings History for INSY - CNBC
StockMarketWatch View the INSY Earnings - StockMarketWatch MacroAxis View INSY Buy or Sell Recommendations - MacroAxis
Bullish View the INSY Bullish Patterns - American Bulls Short Pains View INSY Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View INSY Stock Mentions - StockTwits PennyStocks View INSY Stock Mentions - PennyStockTweets
Twitter View INSY Stock Mentions - Twitter Invest Hub View INSY Investment Forum News - Investor Hub
Yahoo View INSY Stock Mentions - Yahoo! Message Board Seeking Alpha View INSY Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for INSY - SECform4.com Insider Cow View Insider Transactions for INSY - Insider Cow
CNBC View INSY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for INSY - OTC Markets
Yahoo View Insider Transactions for INSY - Yahoo! Finance NASDAQ View Institutional Holdings for INSY - NASDAQ


Stock Charts

FinViz View INSY Stock Insight & Charts - FinViz.com StockCharts View INSY Investment Charts - StockCharts.com
BarChart View INSY Stock Overview & Charts - BarChart Trading View View INSY User Generated Charts - Trading View




Latest Financial News for INSY


These Cannabis Stocks Are Soaring in January
Posted on Wednesday January 16, 2019

These Cannabis Stocks Are Soaring in JanuaryCannabis stock trendsCannabis stock CannTrust Holdings (CNTTF) rose to $6.0 on January 15 from $4.8 at the close of market on December 31, 2018, representing a rise of ~25% in the first half of January


Here's Why Marijuana Stock Insys Therapeutics Fell More Than 63% in 2018
Posted on Monday January 14, 2019

The opioid business isn't what it used to be.


How INSYS Therapeutics’ Earnings Were Trending
Posted on Monday January 14, 2019

Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively, compared to $180.8 million and $2.50 in the same period the prior year. In the third quarter, INSYS Therapeutics reported net income and diluted EPS of $30.4 million and $0.41, respectively, compared to $166.3 million and $2.28 in the third quarter of 2017. Wall Street analysts anticipate that INSYS Therapeutics is expected to report net income and EPS of $29.21 million and $0.39, respectively, in the fourth quarter of 2018. Analysts also estimate that the company is expected to report net income and EPS of $105.1 million and $1.51, respectively, in fiscal 2018. ## Gross income and profit margin In the first nine months of 2018, INSYS Therapeutics’ (INSY) gross income amounted to $57.4 million compared to $93.1 million in the same period the prior year. In the third quarter, the company’s gross income amounted to $15.97, which is a ~31% YoY decline. Wall Street analysts anticipate INSYS Therapeutics to report gross income of $16.20 million in the fourth quarter of 2018. Analysts also predict that the company’s gross income for fiscal 2018 will be $74.03 million, which represents a ~38.33% YoY decline. In the third quarter, INSYS Therapeutics reported a gross margin of ~87% compared to 75.6% in the third quarter of 2017. ## Recent developments On January 9, INSYS Therapeutics presented results of the dose-evaluation pharmacokinetic study of the company’s epinephrine nasal spray. In the pharmacokinetic study, a dose was identified that is comparable to that of Adrenalin (0.5 mg) and EpiPen (0.3 mg). Adrenalin (0.5 mg) and EpiPen (0.3 mg) both are utilized for the treatment of anaphylaxis. In July 2018, INSYS Therapeutics’ proof-of-concept pharmacokinetic trial epinephrine nasal spray showed rapid drug absorption through the nasal mucosa. The bioavailability of epinephrine nasal spray was demonstrated to be similar to the intramuscular injection of EpiPen (0.3mg). In August 2018, INSYS Therapeutics’ epinephrine nasal spray was granted a fast track designation by the US FDA as investigational therapy for treatment of anaphylaxis. Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 2 - How Is INSYS Therapeutics Financially Positioned in January?


How Is INSYS Therapeutics Financially Positioned in January?
Posted on Friday January 11, 2019

Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million. In the third quarter, the company’s revenues declined ~40% YoY to reach $18.3 million from $30.7 million. Wall Street analysts estimate that INSYS Therapeutics is expected to generate revenues of $17.95 million in the fourth quarter of fiscal 2018, which represents a ~42.99% YoY decline. Analysts also estimate that INSYS Therapeutics will report net revenues of $83.74 million for fiscal 2018, which represents a ~40.48% YoY decline. Analysts estimate that GW Pharmaceuticals (GWPH) and Cara Therapeutics (CARA), INSYS Therapeutics’ peers in the cannabinoid drugs market, will report net revenues of $8.7 million and $10.9 million, respectively. GW Pharmaceuticals is expected to deliver ~13.52% YoY revenue growth in fiscal 2018. INSYS Therapeutics and Lunatus signed a licensing agreement for the commercialization of Subsys in the Middle East market. The agreement could boost INSYS Therapeutics’ global footprint and business growth. ## Expenditure trends In the first nine months of 2018, INSYS Therapeutics’ cost of revenue amounted to $8.2 million compared to $16.0 million in the same period the prior year. Wall Street analysts anticipate INSYS Therapeutics’ cost of revenue to be around $9.7 million in fiscal 2018. In the first nine months of 2018, INSYS Therapeutics’ net expenses in sales and marketing (or S&M) amounted to $25.5 million compared to $41.7 million in the same period the prior year. INSYS Therapeutics reported R&D (research & development) and G&A (general & administrative) expenses of $43.2 million and $29.3 million, respectively, compared to $46.6 million and $31.8 million in the same period the prior year. Wall Street analysts estimate that the company’s S&M, G&A, and R&D expenditure will be around $32.49 million, $89.50 million, and $58.78 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 3 - How INSYS Therapeutics’ Earnings Were Trending


Stock Market & Investing Books

Enter a stock symbol to view the stock details.